Nara
← Intervention Library

Emerging

NAD+ precursors

NMN and NR, studied for declining NAD+ availability with age.

Nara’s current positionResearch watchlist
Evidence briefing

Strongest directness: Canine biomarkers. Last reviewed 2026-08-12.

Nara’s evidence view

Research watchlist

PreliminaryCanine biomarkersLow confidence

The claim we’re evaluating

NMN or NR supplementation improves healthy-aging functional outcomes or lifespan in dogs.

Nara’s interpretation

NAD+ biology is compelling, but increasing NAD+ or changing NAD-related biomarkers does not by itself demonstrate better healthspan or lifespan. NMN has limited direct canine intervention evidence involving short-term safety and inflammatory biomarkers, whereas convincing isolated NR outcome evidence in dogs was not identified. Human NMN and NR trials make the pathway scientifically credible enough to follow, but Nara should not present either precursor as a proven canine anti-aging intervention.

This is an umbrella assessment. The evidence differs materially depending on the outcome and the specific form of the intervention, so Nara evaluates those narrower claims separately.

Personalized

What this means for your dog.

Loading your dog’s context…

Evidence briefing

What Nara knows now.

A bounded position while the full claim-level dossier is still being completed.

What is known

NMN and NR need to remain separate. For NMN, a short-term oral toxicity study in Beagles provides direct canine safety information and reported modest changes including creatinine and uric acid at the studied exposure, while a 2024 aging-focused canine investigation reported changes in inflammatory biomarkers after NMN administration; these data do not establish functional benefit. No verified isolated canine NR efficacy trial was identified through the cutoff. A 2024 senior-dog randomized trial of a proprietary NAD+ precursor combined with a senolytic reported a greater owner-assessed cognitive signal in the full-intervention group, but objective cognitive and activity testing did not establish corresponding improvement and the design cannot attribute any effect to NMN, NR or NAD+ elevation. Human NMN trials demonstrate NAD-related biological effects and some population-specific metabolic or functional signals; NR has also shown a preliminary walking-performance benefit in peripheral artery disease. None demonstrates canine lifespan extension, and biomarker elevation of NAD+ is not itself a health outcome.

What is not known

NMN and NR are distinct interventions and cannot inherit one another's efficacy evidence. The direct canine NMN evidence is predominantly safety and biomarker evidence rather than physical, cognitive, healthspan or lifespan outcomes. No convincing isolated canine NR functional-outcome trial was identified through the cutoff. The senior-dog combination trial used a proprietary NAD+ precursor together with a senolytic, preventing attribution of effects to the NAD+ precursor or to NMN or NR specifically. In the combination trial, owner-assessed cognitive change and objective testing did not provide a uniformly concordant efficacy signal. Human trials involve specific populations and outcomes and cannot establish benefit in healthy or aging dogs. Raising NAD+ is a pharmacodynamic or biochemical effect, not evidence by itself of improved healthspan or lifespan.

Current position

NAD+ biology is compelling, but increasing NAD+ or changing NAD-related biomarkers does not by itself demonstrate better healthspan or lifespan. NMN has limited direct canine intervention evidence involving short-term safety and inflammatory biomarkers, whereas convincing isolated NR outcome evidence in dogs was not identified. Human NMN and NR trials make the pathway scientifically credible enough to follow, but Nara should not present either precursor as a proven canine anti-aging intervention.

NMN and NR need to remain separate. For NMN, a short-term oral toxicity study in Beagles provides direct canine safety information and reported modest changes including creatinine and uric acid at the studied exposure, while a 2024 aging-focused canine investigation reported changes in inflammatory biomarkers after NMN administration; these data do not establish functional benefit. No verified isolated canine NR efficacy trial was identified through the cutoff. A 2024 senior-dog randomized trial of a proprietary NAD+ precursor combined with a senolytic reported a greater owner-assessed cognitive signal in the full-intervention group, but objective cognitive and activity testing did not establish corresponding improvement and the design cannot attribute any effect to NMN, NR or NAD+ elevation. Human NMN trials demonstrate NAD-related biological effects and some population-specific metabolic or functional signals; NR has also shown a preliminary walking-performance benefit in peripheral artery disease. None demonstrates canine lifespan extension, and biomarker elevation of NAD+ is not itself a health outcome.